OptiNose

OptiNose — Q3 2024 Earnings Presentation

16 slides from OptiNose's earnings presentation, Nov 12, 2024

  1. Slide 1: Building a Leading ENT / Allergy Specialty Company

    Building a Leading ENT / Allergy Specialty Company Corporate Presentation November 12, 2024

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this

  3. Slide 3: Today's Agenda

    3 Today’s Agenda Introduction and Key Takeaways Ramy Mahmoud, MD, MPH CS Launch Update Paul Spence Q3 2024 Performance and Updated FY 2024 Financial Guidance Terry Kohler Closing Remarks Ramy Mahmoud, MD, MPH

  4. Slide 4: Key Takeaways

    4 Key Takeaways • New indication creates a significant near-term growth opportunity with up to a 10x multiple on the TAM based on patients who are currently treated by a physician • Current sales footprint of 75 territories and phased modest incremental commercial investment, expected to be sufficie

  5. Slide 5: CS Launch Updates

    gis le CS Launch Updates

  6. Slide 6: Commercial Update

    6 Commercial Update • Delivery of on-target, efficacy-focused discussions, at sufficient frequency, is critical to driving product adoption. We re- engineered sales practices to better focus on productive discussions that generate promotional response. • While approximately 70% of lives are in an in

  7. Slide 7: New Prescriptions (NRx)

    7 New Prescriptions (NRx) • The four-week moving average of weekly XHANCE NRx inflected positively in mid- to late-September • The most recent 6 weeks of XHANCE NRx include the top 5 weeks of NRx in 2024 • Q3 changes in commercial efforts include: • Enhanced sales force execution, including targetin

  8. Slide 8: Q3 2024 Performance

    Q3 2024 Performance

  9. Slide 9: Financial Review – Third Quarter 2024

    9 Financial Review – Third Quarter 2024 Average net revenue per prescription increased 36% YoY in context of our focus on growing profitable prescriptions XHANCE Net Revenues of $20.4 million increased 3% compared to Q3 2023 Operating Expenses increased ~$1M to support the CS launch $19.3 $20.4 0 10

  10. Slide 10: Financial Review – YTD September 2024

    10 Financial Review – YTD September 2024 Average net revenue per prescription increased 45% YoY in context of our focus on growing profitable prescriptions XHANCE Net Revenues of $55.8 million increased 9% compared to YTD September 2023 Operating Expenses increased ~$2M to support the CS launch $64.

  11. Slide 11: 2024 Outlook

    optinose__ ————— 2024 Outlook

  12. Slide 12: Full Year 2024 Financial Guidance

    12 Full Year 2024 Financial Guidance XHANCE Net Revenue FY 2024 expected to be between $75 to $79 million (Previously expected to be between $85 to $90 million) XHANCE Average Net Revenue per Prescription FY 2024 expected to be approximately $270, an increase of ~29% compared to full year 2023 (Prev

  13. Slide 13: Closing Remarks

    Closing Remarks

  14. Slide 14: Key Takeaways

    14 Key Takeaways • New indication creates a significant near-term growth opportunity with up to a 10x multiple on the TAM based on patients who are currently treated by a physician • Current sales footprint of 75 territories and phased modest incremental commercial investment, expected to be suffici

  15. Slide 15: Investor Relations – Optinose

    15 Investor Relations – NASDAQ: OPTN Optinose Investor ContactAnalyst Coverage 1 Jefferies: Glen Santangelo Lake Street: Thomas Flaten Piper Sandler: David Amsellem H. C. Wainwright: Matthew Caufield 1 - Optinose is followed by the analysts listed above. Please note that any opinions, estimates or f

  16. Slide 16: Building a Leading ENT / Allergy Specialty Company

    Building a Leading ENT / Allergy Specialty Company Corporate Presentation November 12, 2024

Optinose — Q3 2024 Earnings Presentation on 6ix